Nurses Compass
Drug Guide
Technetium Tc-99m Mertiatide
Classification
Therapeutic: Diagnostic agent
Pharmacological: Radiopharmaceutical
FDA Approved Indications
- Renal imaging to evaluate renal perfusion, function, and drainage
Mechanism of Action
Technetium Tc-99m Mertiatide is a radiotracer that is actively taken up by renal tubular cells, allowing imaging of renal perfusion and function through gamma camera scintigraphy.
Dosage and Administration
Adult: Administer as per specific imaging protocol, typically via intravenous injection. Dose varies based on patient size and imaging requirements.
Pediatric: Dose determined based on body weight or surface area; consult specific pediatric dosing guidelines.
Geriatric: Adjust dose as needed based on renal function and overall health.
Renal Impairment: Dose adjustments may be necessary; assess renal function prior to administration.
Hepatic Impairment: No specific adjustment; use with caution as hepatic clearance is minimal.
Pharmacokinetics
Absorption: Administered intravenously, so absorption is immediate.
Distribution: Distributed primarily to renal tissue; minimal extrarenal distribution.
Metabolism: Not metabolized; remains in unchanged radiotracer form.
Excretion: Excreted unchanged via renal pathway.
Half Life: Approximate physical half-life of Tc-99m is 6 hours; biological half-life in renal tissue varies.
Contraindications
- Known hypersensitivity to Technetium Tc-99m Mertiatide or its components.
Precautions
- Use with caution in pregnant or nursing women; there is radiation exposure.
- Ensure proper handling and disposal of radioactive materials.
Adverse Reactions - Common
- Rash (Rare)
- Discomfort at injection site (Rare)
Adverse Reactions - Serious
- Allergic reactions including anaphylaxis (Very rare)
Drug-Drug Interactions
- None specifically identified; avoid other radiopharmaceuticals within a short interval if possible.
Drug-Food Interactions
- No significant food interactions.
Drug-Herb Interactions
- No established interactions.
Nursing Implications
Assessment: Ensure proper patient identification and assessment of renal function prior to imaging.
Diagnoses:
- Risk for impaired renal function
Implementation: Administer the radiotracer as ordered; monitor for adverse reactions; ensure radiation safety protocols are followed.
Evaluation: Assess image quality and confirm that renal function and perfusion are adequately visualized.
Patient/Family Teaching
- Explain that a small amount of radioactive material will be injected for imaging.
- Advise about the temporary nature of radiation exposure and safety precautions.
- Report any unusual symptoms post-procedure.
Special Considerations
Black Box Warnings:
- Radiation exposure risk; use only as indicated.
- Ensure proper handling to minimize radiation dose to patient and staff.
Genetic Factors: None known.
Lab Test Interference: Radiotracer may interfere with some lab tests; inform laboratory personnel of the procedure.
Overdose Management
Signs/Symptoms: No specific overdose symptoms known; overdose could theoretically increase radiation exposure.
Treatment: Supportive care; minimize additional radiation exposure; symptomatic treatment as needed.
Storage and Handling
Storage: Store in a lead-shielded container at room temperature.
Stability: Stable until expiration date if maintained properly.